Dear Editor, We read with great interest the study of Moriguchi et al. [1] regarding the efficacy of hepatic arterial infusion of chemotherapy (HAIC) in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). HAIC has been proposed to be beneficial for patients with advanced HCC owing to a numerically higher response rate than with sorafenib. We would like to share a unique case of a patient with advanced HCC and Child-Pugh (CP) class C liver reserve to endorse the findings of Moriguchi et al. [1] .
raphy revealed biliary obstruction resolution; therefore, the drainage tube was removed. The total bilirubin level stabilized to approximately 1 mg/dL, and the albumin level increased to 4 g/dL. The patient's liver reserve was thus reclassified as CP class A (Fig. 2) . All HAIC cycles were well tolerated with no grade 3 or 4 toxicities. The most severe adverse effect was a grade 2 thrombocytopenia that did not require a dose adjustment. A serial follow-up CT scan after 12 cycles of HAIC showed a sustained positive response to HAIC (Fig. 1E, F) .
New lung metastases were identified 6 months later, and HAIC was discontinued. At that time, a total of 19 HAIC cycles were given within 18 months. Upon disease progression, the patient remained in CP class A liver reserve; therefore, sorafenib was given as subsequent treatment. Four months after the new metastases had been diagnosed, the patient continued to be treated with sorafenib and has now survived more than 2 years since the initial diagnosis of advanced HCC.
This case demonstrated the potential of using HAIC in patients with advanced HCC and poor liver reserve. HAIC might provide a higher response rate than sorafenib, although no randomized studies have been conducted [3] . This patient's liver reserve improved substantially from CP class C to A during the HAIC treatment course. Consequently, treatment with sorafenib was possible after the disease progressed on HAIC treatment. This patient survived for more than 2 years, which is much longer than the reported median survival of patients with advanced HCC and CP class C liver reserve (1.5-4.0 months) [4] .
We did not choose targeted agents, such as sorafenib, or immunotherapy as a first-line therapy for this patient. Most targeted agents have benefits for patients with advanced HCC through disease stabilization rather than tumor shrinkage. Immunotherapy with checkpoint inhibitors, such as nivolumab, might provide a higher response rate (20%), but the median time to response is 4.1 months [5] . Because our patient had a considerably large liver tumor with impending hepatic failure, disease stabilization or a slow tumor response might not have been ideal. Therefore, we considered HAIC an attractive treatment option.
Approved therapy is not available for patients with advanced HCC and CP class B or C liver reserves. Among patients who received sorafenib, the median survival was approximately 5.2 and 2.6 months for patients with CP class B and C liver reserve, respectively [4] . HAIC has been reported to provide a numerically comparable median survival in patients with CP class B or C liver reserve [6, 7] . Adverse effects from HAIC treatment are not significantly worse in patients with CP class B and C liver reserve than in patients with CP class A [6] . Device issues were infrequent with experienced physicians and institutes. HAIC may serve as a viable treatment option in selected patients with CP class B or C liver reserve.
In conclusion, we report the success of HAIC in a patient with advanced HCC and impending liver failure. The treatment resulted in a dramatic tumor response, an improved liver reserve, and prolonged survival. 
